Latest filing published 26 Jun 2026 for Journey Medical Corp.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Lindsay A. Rosenwald MD across 10 companies, led by Fortress Biotech, Inc., Checkpoint Therapeutics, Inc. and Mustang Bio, Inc. Between 15 May 2006 and 25 June 2026, the trades on record add up to 122 filings.
The open-market side counts 61 purchases for €10.7M alongside 3 sales for €890k. The totals exclude 1 filing filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 49 share grants.
A typical purchase (the median) is worth €27k. 16 out of 42 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.
The latest filing, published on 26 June 2026, reports a share grant in Journey Medical Corp. The clock since the last published purchase (25 September 2024) now reads 759 days. The median gap between a trade and its publication by SEC (Form 4) is 4 days. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
25 of 41 declarations